GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Entia Biosciences ERGO · USD

Consumer Staples · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2016

Revenue

$265,466

FY2014FY2016

Net income

−$1.5m

FY2014FY2016

Free cash flow

−$722,215

FY2014FY2016

Shareholders' equity

−$2.0m

FY2014FY2016

Income statement

Fiscal years

FY2016FY2015FY2014
Revenue$265,466$346,910$656,342
Gross profit$173,967$215,903$410,871
Research and development$37,750$73$25
Operating income−$1.2m−$1.9m−$1.8m
Net income−$1.5m−$2.4m−$2.6m
Diluted earnings per share-0.05-0.08-0.24

Balance sheet

At each fiscal year end

FY2016FY2015FY2014
Total assets$439,141$448,606$870,708
Cash and short-term investments$76,050$24,133$99,462
Total liabilities$2.4m$1.2m$987,244
Debt$1.0m$279,237$418,075
Shareholders' equity−$2.0m−$791,188−$116,536
Shares outstanding28m29m11m

Cash flow

Fiscal years

FY2016FY2015FY2014
Cash from operations−$715,098−$536,565−$680,284
Capital spending−$7,117−$21,286−$45,464
Free cash flow−$722,215−$557,851−$725,748

Latest quarters

By quarter end

Dec 2016Sept 2016Jun 2016Mar 2016Dec 2015Sept 2015Jun 2015Mar 2015
Revenue$45,986$41,855$98,425$79,200$68,397$68,048$108,136$102,329
Gross profit$35,866$28,426$62,832$46,843$37,330$46,456$61,413$70,704
Operating income−$335,740−$271,373−$290,349−$269,911−$170,982−$333,791−$950,371−$460,813
Net income−$469,743−$303,410−$419,519−$279,986−$310,018−$366,922−$1.1m−$520,509
Diluted earnings per share-0.02-0.01-0.01-0.01-0.01-0.01-0.04-0.02
Total assets$439,141$365,827$399,798$405,772$448,606$609,138$758,400$736,615
Cash and short-term investments$76,050$2,020$17,758$44,938$24,133$41,354$182,029$179,149
Debt$745,922$254,175$193,323$208,681$279,237$138,520$166,444$379,684
Shareholders' equity−$2.0m−$1.6m−$1.4m−$1.0m−$791,188−$291,289−$82,330−$318,655

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return100%100%-33%88%180%7279%977%4796%618%29%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 15 Feb 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.